Public Citizen seeks Avandia ban
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline's troubled diabetes drug Avandia (rosiglitazone) is coming under renewed pressure after the US public interest group Public Citizencalled upon the US FDA to ban the drug because of new safety concerns. The move comes just days after a panel of experts representing the American Diabetes Association and the European Association for the Study of Diabetes issued revised treatment recommendations for type 2 diabetes in which they advise against using the product.
You may also be interested in...
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.
10 Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are ten (plus a few extras) that have caught Scrip’s eye for one reason or another, eg, for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.
Triumvira Takes A Different TAC With T-Cell Therapy For Solid Tumors
The private US/Canadian firm is taking a singular approach to T-cell therapy to tackle both solid and liquid tumors and hopes to have early data to back up its novel technology this year. An IPO could follow.